Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short-stature syndromes

Human Molecular Genetics

Volumn 25, Issue 1, 2016, Pages 9-23

  Gudernova, Iva ^a   Vesela, Iva ^b,c   Balek, Lukas ^a   Buchtova, Marcela ^a,b   Dosedelova, Hana ^b,c   Kunova, Michaela ^a   Pivnicka, Jakub ^a   Jelinkova, Iva ^a   Roubalova, Lucie ^d   Kozubik, Alois ^a,e   Krejci, Pavel ^a,f  

^a MASARYK UNIVERSITY   (Czech Republic)

^b INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^c UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^d UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^e INSTITUTE OF BIOPHYSICS   (Czech Republic)

^f ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ABELSON KINASE; AZD 4547; CD135 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR; INFIGRATINIB; JANUS KINASE 3; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN RECEPTOR 3; 3-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-1-(6-(4-(4-ETHYLPIPERAZIN-1-YL)-PHENYLAMINO)PYRIMIDIN-4-YL)-1-METHYLUREA; BENZAMIDE DERIVATIVE; CARBANILAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE GROWTH; CARTILAGE CELL; CATALYSIS; CELL CULTURE; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; KINASE ASSAY; LIVER TOXICITY; LUNG TOXICITY; MOUSE; NEPHROTOXICITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SHORT STATURE; ACHONDROPLASIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CARTILAGE; CHICK EMBRYO; DRUG EFFECTS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; SYNDROME;

ACHONDROPLASIA; ANIMALS; BENZAMIDES; CARTILAGE; CATALYSIS; CELLS, CULTURED; CHICK EMBRYO; CHONDROCYTES; HUMANS; MICE; PHENYLUREA COMPOUNDS; PIPERAZINES; PYRAZOLES; PYRIMIDINES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; SYNDROME;

EID: 84962189588     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv441     Document Type: Article

References (54)

1. Provot, S. and Schipani, E. (2005) Molecular mechanisms of endochondral bone development. Biochem. Biophys. Res. Commun., 328, 658-665
2. Kronenberg, H.M. (2006) PTHrP and skeletal development. Ann. N. Y. Acad. Sci., 1068, 1-13
3. Pogue, R. and Lyons, K. (2006) BMP signaling in the cartilage growth plate. Curr. Top. Dev. Biol., 76, 1-48
4. Pejchalova, K., Krejci, P. and Wilcox, W.R. (2007) C-natriuretic peptide: an important regulator of cartilage. Mol. Genet. Metab., 92, 210-215
5. Dagoneau, N., Scheffer, D., Huber, C., Al-Gazali, L.I., Di Rocco, M., Godard, A., Martinovic, J., Raas-Rothschild, A., Sigaudy, S., Unger, S. et al. (2004) Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. Am. J. Hum. Genet., 74, 298-305
6. Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. and Ornitz, D.M. (1996) Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat. Genet., 12, 390-397
7. Toydemir, R.M., Brassington, A.E., Bayrak-Toydemir, P., Krakowiak, P.A., Jorde, L.B., Whitby, F.G., Longo, N., Viskochil, D. H., Carey, J.C. and Bamshad, M.J. (2006) A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am. J. Hum. Genet., 79, 935-941
8. Chen, L., Adar, R., Yang, X., Monsonego, E.O., Li, C., Hauschka, P.V., Yayon, A. and Deng, C.X. (1999) Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J. Clin. Invest., 104, 1517-1525
9. Murakami, S., Balmes, G., McKinney, S., Zhang, Z., Givol, D. and de Crombrugghe, B. (2004) Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev., 18, 290-305
10. Parker, H.G., VonHoldt, B.M., Quignon, P., Margulies, E.H., Shao, S., Mosher, D.S., Spady, T.C., Elkahloun, A., Cargill, M., Jones, P.G. et al. (2009) An expressed fgf4 retrogene is associated with breed-defining chondrodysplasia in domestic dogs. Science, 325, 995-998
11. Foldynova-Trantirkova, S., Wilcox, W.R. and Krejci, P. (2012) Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum. Mutat., 33, 29-41
12. Horton, W.A., Hall, J.G. and Hecht, J.T. (2007) Achondroplasia. Lancet, 370, 162-172
13. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J. and Lydon, N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2, 561-566
14. Wesche, J., Haglund, K. and Haugsten, E.M. (2011) Fibroblast growth factors and their receptors in cancer. Biochem. J., 437, 199-213
15. Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B.K., Hubbard, S.R. and Schlessinger, J. (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science, 276, 955-960
16. Mohammadi, M., Froum, S., Hamby, J.M., Schroeder, M.C., Panek, R.L., Lu, G.H., Eliseenkova, A.V., Green, D., Schlessinger, J. and Hubbard, S.R. (1998) Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J., 17, 5896-5904
17. Hamby, J.M., Connolly, C.J., Schroeder, M.C., Winters, R.T., Showalter, H.D., Panek, R.L., Major, T.C., Olsewski, B., Ryan, M.J., Dahring, T. et al. (1997) Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem., 40, 2296-2303
18. Gavine, P.R., Mooney, L., Kilgour, E., Thomas, A.P., Al-Kadhimi, K., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J. et al. (2012) AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res., 72, 2045-2056
19. Guagnano, V., Furet, P., Spanka, C., Bordas, V., Le Douget, M., Stamm, C., Brueggen, J., Jensen, M.R., Schnell, C., Schmid, H. et al. (2011) Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl)-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem., 54, 7066-7083
20. Liang, G., Chen, G., Wei, X., Zhao, Y. and Li, X. (2013) Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine Growth Factor Rev., 24, 467-475
21. Carter, E.P., Fearon, A.E. and Grose, R.P. (2014) Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol., 25, 221-33
22. Laederich, M.B. and Horton, W.A. (2010) Achondroplasia: pathogenesis and implications for future treatment. Curr. Opin. Pediatr., 22, 516-523
23. Jonquoy, A., Mugniery, E., Benoist-Lasselin, C., Kaci, N., Le Corre, L., Barbault, F., Girard, A.L., Le Merrer, Y., Busca, P., Schibler, L. et al. (2012) A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model. Hum. Mol. Genet., 21, 841-851
24. Mukhopadhyay, K., Lefebvre, V., Zhou, G., Garofalo, S., Kimura, J.H. and de Crombrugghe, B. (1995) Use of a new rat chondrosarcoma cell line to delineate a 119-base pair chondrocyte-specific enhancer element and to define active promoter segments in the mouse pro-alpha 1(II) collagen gene. J. Biol. Chem., 270, 27711-27719
25. Krejci, P., Salazar, L., Goodridge, H.S., Kashiwada, T.A., Schibler, M.J., Jelinkova, P., Thompson, L.M. and Wilcox, W.R. (2008) STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes. J. Cell. Sci., 121, 272-281
26. Krejci, P., Prochazkova, J., Smutny, J., Chlebova, K., Lin, P., Aklian, A., Bryja, V., Kozubik, A. and Wilcox, W.R. (2010) FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence. Bone, 47, 102-110
27. Krejci, P., Pejchalova, K. and Wilcox, W.R. (2007) Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway. Invest. New. Drugs, 25, 391-395
28. Krejci, P., Bryja, V., Pachernik, J., Hampl, A., Pogue, R., Mekikian, P. and Wilcox, W.R. (2004) FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Exp. Cell. Res., 297, 152-164
29. Buchtova, M., Oralova, V., Aklian, A., Masek, J., Vesela, I., Ouyang, Z., Obadalova, T., Konecna, Z., Spoustova, T., Pospisilova, T. et al. (2015) Fibroblast growth factor and canonical WNT/ß-catenin signaling cooperate in suppression of chondrocyte differentiation in experimental models of FGFR signaling in cartilage. Biochim. Biophys. Acta, 1852, 839-850
30. Krejci, P., Masri, B., Salazar, L., Farrington-Rock, C., Prats, H., Thompson, L.M. and Wilcox, W.R. (2007) Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J. Biol. Chem., 282, 2929-2936
31. Sahni, M., Ambrosetti, D.C., Mansukhani, A., Gertner, R., Levy, D. and Basilico, C. (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes. Dev., 13, 1361-1366
32. Wendt, D.J., Dvorak-Ewell, M., Bullens, S., Lorget, F., Bell, S.M., Peng, J., Castillo, S., Aoyagi-Scharber, M., O'Neill, C.A., Krejci, P. et al. (2015) Neutral endopeptidase resistant C-type natriuretic peptide (CNP) variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J. Pharmacol. Exp. Ther., 353, 132-149
33. Le Corre, L., Girard, A.L., Aubertin, J., Radvanyi, F., Benoist-Lasselin, C., Jonquoy, A., Mugniery, E., Legeai-Mallet, L., Busca, P. and Le Merrer, Y. (2010) Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors. Org. Biomol. Chem., 8, 2164-2173
34. White, K.E., Cabral, J.M., Davis, S.I., Fishburn, T., Evans, W.E., Ichikawa, S., Fields, J., Yu, X., Shaw, N.J., McLellan, N.J. et al. (2005) Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am. J. Hum. Genet., 76, 361-367
35. Passos-Bueno, M.R., Wilcox, W.R., Jabs, E.W., Sertié, A.L., Alonso, L.G. and Kitoh, H. (1999) Clinical spectrum of fibroblast growth factor receptor mutations. Hum. Mutat., 14, 115-125
36. Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P.A., Stratton, M. R. et al. (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer, 91, 355-358
37. Taylor, J.G. VI, Cheuk, A.T., Tsang, P.S., Chung, J.Y., Song, Y.K., Desai, K., Yu, Y., Chen, Q.R., Shah, K., Youngblood, V. et al. (2009) Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest., 119, 3395-3407
38. Krejci, P., Salazar, L., Kashiwada, T.A., Chlebova, K., Salasova, A., Thompson, L.M., Bryja, V., Kozubik, A. and Wilcox, W.R. (2008) Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS One, 3, e3961
39. Huang, Z., Tan, L., Wang, H., Liu, Y., Blais, S., Deng, J., Neubert, T.A., Gray, N.S., Li, X. and Mohammadi, M. (2015) DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors. ACS Chem. Biol., 10, 299-309
40. Horakova, D., Cela, P., Krejci, P., Balek, L., Moravcova Balkova, S., Matalova, E. and Buchtova, M. (2014) Effect of FGFR inhibitors on chicken limb development. Dev. Growth Differ., 56, 555-572
41. Daniels, K., Reiter, R. and Solursh, M. (1996) Micromass cultures of limb and other mesenchyme. Methods Cell. Biol., 51, 237-247
42. Kim, J.H., Lee, M.C., Seong, S.C., Park, K.H. and Lee, S. (2011) Enhanced proliferation and chondrogenic differentiation of human synovium-derived stem cells expanded with basic fibroblast growth factor. Tissue Eng. Part A, 17, 991-1002
43. Buchtova, M., Chaloupkova, R., Zakrzewska, M., Vesela, I., Cela, P., Zajickova, R., Trantirek, L., Martin, J., Kostas, M., Otlewski, J. et al. (2015) Instability Restricts Signaling of Multiple Fibroblast Growth Factors. Cell. Mol. Life Sci., 72, 2445-59
44. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. and Leder, P. (1996) Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell, 84, 911-921
45. Peters, K.G., Werner, S., Chen, G. and Williams, L.T. (1992) Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. Development, 114, 233-243
46. Peters, K., Ornitz, D., Werner, S. and Williams, L. (1993) Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev. Biol., 155, 423-430
47. Delezoide, A.L., Benoist-Lasselin, C., Legeai-Mallet, L., Le Merrer, M., Munnich, A., Vekemans, M. and Bonaventure, J. (1998) Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification. Mech. Dev., 77, 19-30
48. Sheeba, C.J., Andrade, R.P., Duprez, D. and Palmeirim, I. (2010) Comprehensive analysis of fibroblast growth factor receptor expression patterns during chick forelimb development. Int. J. Dev. Biol., 54, 1517-1526
49. Laron, Z. (2001) Insulin growth factor 1 (IGF-1): a growth hormone. Mol. Pathol., 54, 311-316
50. Krejci, P., Aklian, A., Kaucka, M., Sevcikova, E., Prochazkova, J., Masek, J.K., Mikolka, P., Pospisilova, T., Spoustova, T., Weis, M. et al. (2012) Receptor tyrosine kinases activate canonical WNT/ß-catenin signaling via MAP kinase/LRP6 pathway and direct ß-catenin phosphorylation. PLoS One, 7, e35826
51. Holland, L.Z., Holland, P.W.H. and Holland, N.D. (1996) Revealing homologies between body parts of distantly related animals by in situ hybridization to developmental genes: amphioxus versus vertebrates. In Ferraris, J. D. and Palumbi, S. R. (eds), Molecular Zoology: Advances, Strategies, and Protocols. New York, Wiley, pp. 267-282, 473-483
52. Bookout, A.L. and Mangelsdorf, D.J. (2003) Quantitative realtime PCR protocol for analysis of nuclear receptor signaling pathways. Nucl. Recept. Signal., 1, e012
53. Abramyan, J., Wilhelm, D. and Koopman, P. (2010) Molecular characterization of the Bidder's organ in the cane toad (Bufo marinus). J. Exp. Zool. B Mol. Dev. Evol., 314, 503-513
54. Hamburger, V. and Hamilton, H.L. (1951) A series of normal stages in the development of the chick embryo. J. Morphol., 88, 49-92